Biodistribution and dosimetry of a single dose of albumin-binding ligand [(177)Lu]Lu-PSMA-ALB-56 in patients with mCRPC

INTRODUCTION: PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for metastatic, castration-resistant prostate cancer (mCRPC). Recently, the concept of modifying PSMA radioligands with an albumin-binding entity was demonstrated as a promising measure to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Nucl Med Mol Imaging
Main Authors: Kramer, Vasko, Fernández, René, Lehnert, Wencke, Jiménez-Franco, Luis David, Soza-Ried, Cristian, Eppard, Elisabeth, Ceballos, Matias, Meckel, Marian, Benešová, Martina, Umbricht, Christoph A., Kluge, Andreas, Schibli, Roger, Zhernosekov, Konstantin, Amaral, Horacio, Müller, Cristina
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8036212/
https://ncbi.nlm.nih.gov/pubmed/32949253
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-020-05022-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados